Round Rock Advisors’s CorMedix CRMD Stock Holding History

Round Rock Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-92,681	Closed	-$629K	–	330
2026 Q1	$629K	Buy	92,681 +677	+0.7%	+$5K	0.1%	167
2025 Q4	$1.07M	Buy	+92,004	New	+$1.02M	0.16%	98

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Round Rock Advisors's CRMD Position: Q2 2026 in Review

Round Rock Advisors sold out of CorMedix (CRMD) in Q2 2026, closing a stake of 92,681 shares — an estimated $629K sold.

Round Rock Advisors first reported a position in CRMD in Q4 2025 and held it in 2 quarters. The position peaked at $1.07M in Q4 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Round Rock Advisors reported no remaining CorMedix position as of Q2 2026 after selling out during the quarter.
Round Rock Advisors sold 92,681 CorMedix shares in Q2 2026, an estimated $629K.
Round Rock Advisors first reported a position in CorMedix in Q4 2025 and held it in 2 quarters.
Round Rock Advisors's CorMedix position peaked at $1.07M in Q4 2025.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Round Rock Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.